worldgraphics-shutterstock-com-italy-flag-
Worldgraphics / Shutterstock.com
10 January 2017BiotechnologyLuca Tosoni

Biosimilars in Italy: a new regime

Since the approval of the first biosimilar in Europe, in 2006, biosimilars have gained momentum. Currently, 25 biosimilars have been centrally approved in the EU, and over a dozen biosimilar applications are under evaluation by the European Medicines Agency. Their number is likely to increase substantially in the next few years due to the upcoming patent expiry of several blockbuster biologics.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
26 June 2026   Deal is aimed at strengthening German company’s presence across high-growth life sciences markets by adding a portfolio of advanced research and analytical technologies.
Biotechnology
25 June 2026   Novartis will work with a US biotech company on new cancer therapies, while Lilly has partnered with a Chinese biopharma firm to develop new medicines.
Biotechnology
22 June 2026   The partnership, announced at BIO 2026, marks the largest Asia-Pacific partnership by potential value that the AI-driven drug discovery company has secured to date.